Human Pathology
Volume 37, Issue 3 , Pages 283-291, March 2006

Prognostic impact of cholangiocellular and sarcomatous components in combined hepatocellular and cholangiocarcinoma

  • Shinichi Aishima, MD

      Affiliations

    • Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
    • Corresponding Author InformationCorresponding authors. Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
  • ,
  • Yousuke Kuroda

      Affiliations

    • Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
  • ,
  • Yoshiki Asayama, MD

      Affiliations

    • Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
  • ,
  • Kenichi Taguchi, MD

      Affiliations

    • Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
  • ,
  • Yunosuke Nishihara

      Affiliations

    • Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
  • ,
  • Akinobu Taketomi, MD

      Affiliations

    • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
  • ,
  • Masazumi Tsuneyoshi, MD

      Affiliations

    • Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
    • Corresponding Author InformationCorresponding authors. Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.

Received 27 January 2005; accepted 3 August 2005.

Summary 

Combined hepatocellular and cholangiocarcinoma (cHC-CC) is a rare type of liver cancer displaying both hepatocellular and cholangiocellular components. The cholangiocellular carcinoma (CC) in these tumors ranges from focal to prominent. Those cHC-CCs with sarcomatous features are reported to have a poor prognosis. To clarify whether the CC and sarcomatous component affects the prognosis, we classified 40 patients with cHC-CCs into 4 groups according to the presence of a sarcomatous component and the extent of the CC component. Seven (17.5%) tumors showed areas with a sarcomatous component. The remaining tumors were divided into a low-CC group (CC occupying <30% of the tumor, n = 12), a middle-CC group (30%-60%, n = 15), and a high-CC group (>60%, n = 6). Vascular invasion was more frequently present in the high-CC and sarcomatous group than in the other groups (P = .0007). No lymph node metastasis occurred in either the low- or the middle-CC groups, but it was detected in 3 (50%) cases of the high-CC group and in 2 (29%) cases of the sarcomatous group (P < .0001). There was a tendency for tumor size to increase from the low- to the middle- to the high-CC group. The Ki-67 labeling index values for the hepatocellular carcinoma, CC, and sarcomatous components were 11.4% ± 12.9%, 25.4% ± 18.3%, and 46.0% ± 23.6%, respectively. The overall survival of patients in the high-CC and sarcomatous group was significantly poorer than that of patients in the low- and middle-CC groups (P = .0048). By multivariate analysis of overall survival, lymph node metastasis, histological subgroup, and vascular invasion were significant independent prognostic factors. A cHC-CC with a large CC component is as aggressive as cHC-CC with sarcomatous features.

Keywords: Combined hepatocellular and cholangiocarcinoma, Sarcomatous component

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was supported in part by a Grant-in-Aid for Scientific Research (15790187) from the Japan Society of the Promotion of Science, Tokyo, Japan.

PII: S0046-8177(05)00472-7

doi:10.1016/j.humpath.2005.08.019

Human Pathology
Volume 37, Issue 3 , Pages 283-291, March 2006